Under vedligeholdelsesbehandlingen var hyppigheden af hjertesygdomme af grad 3/ 4 / sammenlignelig mellem patienter behandlet i MabThera- gruppen og i observationssgruppen.
During maintenance treatment, the incidence of grade 3/ 4 cardiac disorders was comparable between patients treated with MabThera and observation.